FindTrial
Sign In

Prevention and regression of carotid artery IMT with Cilostazol and Pioglitazone use in atherosclerosis with type 2 diabetes

Prevention and regression of carotid artery IMT with Cilostazol and Pioglitazone use in atherosclerosis with type 2 diabetes - PRECIOUS

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000001729
Enrollment
400
Registered
2009-03-01
Start date
2009-03-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Group A Follow up 2-year prospective follow-up study Dose Cilostazol 100-200mg/day, Pioglitazone 15-30 mg/day, Aspirin 100-300 mg/day Measure IMT
After 0,6,12,24 Month Group B Follow up 2-year prospective follow-up srudy Dose
Pioglitazone 15-30 mg/day, Aspirin 100-300 mg/day Measure IMT After 0,6,12,24 Month

Sponsors

CHIBAKEN SAISEIKAI NARASINO HOSPITAL internal medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Type 2 diabetes mellitus 2. Pts receiving pioglitazone therapy for at least 6 months 3. Pts receiving aspirin therapy 4. Age between 50 to 80 years 5. Either outpatient or inpatient

Exclusion criteria

Exclusion criteria: 1. HbA1c and over 10% 2. Medical history or presumptive of carotid arterial reconstruction 3. BNP and over 100 4. Early stage of stroke 5. Arterial fibrillation 6. Under anti-platelet therapy other than aspirin 7. Receiving warfarin-potassium therapy 8. Congestive heart failure 9. Severe hepatic disfunction or renal disfunction 10. Severe infections disease, injury, pre or post operation 11. Severe ketosis, diabetic coma, type 1 diabetes mellitus 12. Pts who are bleeding 13. Drug allergies or medical history of hypersensitivity to the investigational drugs 14. Pregnant or lactating women, or women who wish to become pregnant 15. Others whom the investigator judges inappropriate as subjects for this study

Design outcomes

Primary

MeasureTime frame
Absolute change of carotid Max-IMT—

Countries

Japan

Contacts

Public ContactToshimasa Fujiwara

CHIBAKEN SAISEIKAI NARASINO HOSPITAL internal medicine

047-473-1281

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026